These independent CME/CE activities are supported by educational grants from Bayer Healthcare Pharmaceuticals, Inc.

Onyx Pharmaceuticals



The Advanced Certificate Program in
Hepatocellular Carcinoma Management
  1. Course List
Co-Chairs
faculty image
Gary L. Davis, MD
  • Director, General and Transplant Hepatology
  • Baylor Regional Transplant Institute
  • Baylor University Medical Center
  • Dallas, Texas
    • faculty image
    Jean Francois H. Geschwind, MD
  • Professor of Radiology, Surgery, and Oncology
  • Division Chief, Vascular and Interventional Radiology
  • Director, Interventional Radiology Center
  • Department of Interventional Radiology
  • Johns Hopkins University
  • Baltimore, Maryland
    • Projects In Knowledge is pleased to present The Advanced Certificate Program in Hepatocellular Carcinoma. This program offers CME and CE credit to oncologists, gastroenterologists, hepatologists, radiologists, surgeons, and other clinicians involved in the care of patients with hepatocellular carcinoma.
  • Assess the importance of screening, surveillance, diagnosis, and optimal treatment intervention of patients with or at risk of developing HCC through an understanding of the risk factors, disease burden, imaging, and biomarkers to customize interventions leading to improved patient outcomes.
  • Analyze the benefits of liver transplantation, surgical resection and ablation therapies in eligible patients with HCC to optimize patient outcomes.
  • Compare the benefits of various adjunctive therapies, including ablative therapy, such as radiofrequency ablation (RFA) and chemoembolization; as well as conformal or stereotactic radiation, including radiotherapeutic microspheres, to select single or combined strategies that improve outcomes of patients with HCC.
  • Evaluate the benefits of targeted therapeutic agents, based on their efficacy and safety profiles and mechanisms of action, to improve treatment outcomes in patients with HCC.
  • Assess tumor- and patient-related factors as predictors of response to determine which patients with HCC are likely to benefit from specific therapies to improve their outcomes.
  • Describe the potential role of systemic chemotherapies in combination with targeted agents, in the future treatment of patients with HCC.
    • Liver resection and liver transplantation
    • Ablative therapy
    • Chemoembolization
    • Conformal/stereotactic radiation and radiotherapeutic microspheres
    • Targeted therapies
    • Epidemiology - relationship to HBV and HCV infection
    • Screening—biomarkers, gene array, proteomics, glycomics, and treatment paradigms
    • When is resection indicated
    • The evolving role of liver transplantation
    • Choosing an ablative regimen
    • When is chemoembolization, conformal/stereotactic radiation or radiotherapeutic microspheres warranted
    • Integrating targeted therapies into HCC treatment
    • Targeted agents

    Target Audience

    This series of CME/CE activities is designed for medical oncologists, gastrointestinal oncologists, gastroenterologists, hepatologists, surgeons, interventional radiologists, radiation oncologists, nurses, nurse practitioners, and other clinicians involved in the care of patients with HCC.

     

    Activity Goal

    The goal of these CME/CE activities is to increase clinicians' awareness of clinicians’ awareness of the incidence of HCC and describe state-of-the-science methods for screening patients and selecting and assessing treatment interventions that optimize treatment for patients with HCC.